600196 Shanghai Fosun Pharmaceutical
- 24.17
- -0.17-0.70%
Shanghai Fosun Pharmaceutical News
Express News | The first Yikaida CAR-T cell treatment center in Macau settled in Jinghu Hospital
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
China's medical products administrator granted Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) unit Shanghai Chongqing Yaoyou Pharmaceutical marketing registration approval for its aripip
Fosun Pharmaceutical (02196.HK) plans to hold 2023 and 2024 first quarter results briefings on May 17
Gelonghui, May 9, 丨 Fosun Pharmaceutical (02196.HK) announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”) will disclose its 2023 annual report on March 27, 2024, and the first quarter report of 2024 on April 30, 2024. In order to facilitate investors to have a more comprehensive and in-depth understanding of the Group's (that is, the company and holding subsidiaries/units, the same below) results and operations for 2023 and the first quarter of 2024, the company is scheduled to be held on May 17, 2024 from 15:00-16:30 p.m.
Fosun Pharmaceuticals (02196) guarantees its holding subsidiary
Fosun Pharmaceutical (02196) announced that the company intends to apply for the principal amount of the holding subsidiary Fosun Antekin from the Bank of Chengdu...
Fosun Pharmaceutical (02196): Application for marketing registration of aripiprazole oral tablets for the treatment of schizophrenia was approved by the State Drug Administration
Fosun Pharmaceutical (02196) announced that the marketing registration application for aripiprazole oral tablets (hereinafter referred to as the “new drug”) independently developed by the company's holding subsidiary Shanghai Chongqing Yaoyou Pharmaceutical Co., Ltd. for the treatment of schizophrenia was recently approved by the China Drug Administration.
Express News | Fosun Pharmaceuticals announced that its holding subsidiary was approved for the registration of aripiprazole oral tablets.
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets
The US Food and Drug Administration granted clinical trial approval to Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) for unit Shanghai Henlius Biotechnology's HLX22 tablets indicated fo
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
Express News | Fosun Pharmaceuticals: The holding subsidiary was approved for clinical trials by the US FDA
Express News | Morgan Stanley raised Fosun Pharmaceuticals' H-share rating to overrated.
Fosun Pharmaceuticals (600196): The first quarter met expectations and expected marginal improvement
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 10.157 billion yuan, -7% YoY; attributed/deducted non-net profit of RMB610/609 million, respectively, or -38%/-34% YoY. Business
Fosun Pharma's Q1 Profit Slumps 38%
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) posted a net profit attributable to owners of 609.7 million yuan in the first quarter of 2024, slumping 38.2% from 987 million yuan a year
Shanghai Fosun Pharmaceutical 1Q Operating Revenue CNY10.16B Vs. CNY10.87B >0656.HK
Shanghai Fosun Pharmaceutical 1Q Operating Revenue CNY10.16B Vs. CNY10.87B >0656.HK
Fosun Pharmaceutical (02196.HK): Fosun Pharmaceutical Industries and Kite Pharma plan to renew and provide additional loans totaling no more than 67 million US dollars to Fosun Kate based on their respective shareholding ratios
Fosun Pharmaceutical (02196.HK) announced that in order to meet the business plans and capital requirements of Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate”), it intends to request the shareholders' meeting of the company to approve the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as “Fosun Pharmaceutical Industry”) and Kite Pharma, Inc. (hereinafter referred to as “Kite Pharma”), the other shareholder of Fosun Kate, and Kite Pharma, Inc. (hereinafter referred to as “Kite Pharma”), the total renewal and additional provision of no more than 67 million yuan to Fosun Kate according to their respective shareholding shares in Fosun Kate Borrowings in US dollars (including principal amount) (
復星醫藥：2024年第一季度報告
Fosun Pharmaceutical (02196, 600196.SH) 2024 Quarterly Report: Innovative achievements are being realized at an accelerated pace, and various new products are comprehensively advancing the commercialization process
During the reporting period, Fosun Pharmaceutical achieved revenue of 10.157 billion yuan, excluding COVID-related products, and achieved positive year-on-year growth in revenue. Net cash flow from operating activities was $917 million, up 5.05% year over year.
Express News | Fosun Pharmaceutical (02196.HK): Net profit for the first quarter was 610 million yuan, down 38.22% year on year.
Express News | Fosun Pharmaceuticals: The holding subsidiary received approval for the registration of cycloserine capsules
復星醫藥：二零二三年年報
Analysis
Price Target
No Data
